| NCT ID | NCT00260585 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Esophageal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 1999-06 |
| Primary Completion | 2050-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 1999-06 with a primary completion date of 2050-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.
Eligibility Criteria
Inclusion Criteria: * Known or suspected esophageal or gastroesophageal junction malignancy * Known Barrett's metaplasia * Clinical management of symptomatic gastroesophageal reflux disease (GERD) * Achalasia * Hiatal hernia Exclusion Criteria: * Elevated pre-operative bloodwork will not have the additional biopsies taken. * Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and/or International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.
Contact & Investigator
James D. Luketich, MD
PRINCIPAL INVESTIGATOR
Department of Cardiothoracic Surgery
Frequently Asked Questions
Who can join the NCT00260585 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00260585 currently recruiting?
Yes, NCT00260585 is actively recruiting participants. Contact the research team at wardj@upmc.edu for enrollment information.
Where is the NCT00260585 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT00260585 clinical trial?
NCT00260585 is sponsored by University of Pittsburgh. The principal investigator is James D. Luketich, MD at Department of Cardiothoracic Surgery. The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.